Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 9/20 | 0.44 |
| ▸ | DRD3 | P35462 | 7/20 | 0.42 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.39 |
| ▸ | F10 | P00742 | 2/20 | 0.38 |
| ▸ | KDM4D | Q6B0I6 | 3/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.37 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.37 |
| ▸ | HTR1D | P28221 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28580140 | 1.00 | DRD2 (0.44) | DRD2DRD3KCNA3F10KDM4D | |
| SCHEMBL28580143 | 1.00 | DRD2 (0.44) | DRD2DRD3KCNA3F10KDM4D | |
| SCHEMBL25017935 | 0.86 | F10 (0.41) | DRD2DRD3F10KDM1AMAOB | |
| SCHEMBL30180569 | 0.86 | F10 (0.41) | DRD2DRD3F10KDM1AMAOB | |
| SCHEMBL28578367 | 0.86 | F10 (0.41) | DRD2DRD3F10KDM1AMAOB | |
| SCHEMBL28583328 | 0.85 | F10 (0.38) | DRD2DRD3F10KDM1AMAOB | |
| SCHEMBL28583330 | 0.85 | F10 (0.38) | DRD2DRD3F10KDM1AMAOB | |
| SCHEMBL28582220 | 0.85 | DRD2 (0.42) | DRD2DRD3KCNA3KDM4DKDM1A | |
| SCHEMBL28582219 | 0.85 | DRD2 (0.42) | DRD2DRD3KCNA3KDM4DKDM1A | |
| SCHEMBL28575236 | 0.85 | DRD2 (0.44) | DRD2DRD3KCNA3F10KDM4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3860636-B1 | MATRIPTASE 2 INHIBITORS AND USES THEREOF | DISC MEDICINE INC (US) | 2026-01-28 | — | — | EP | disclosed |
| US-12428415-B2 | Matriptase 2 inhibitors and uses thereof | DISC MEDICINE, INC. (US) | 2025-09-30 | — | — | US | disclosed |
| US-20230043159-A1 | MATRIPTASE 2 INHIBITORS AND USES THEREOF | DISC MEDICINE, INC. | 2023-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12428415-B2 | Matriptase 2 inhibitors and uses thereof | MMP7, MATR3, SPINT2 | DRD2 4828/4885DRD3 4796/4885KCNA3 3851/4885 |
| US-20230043159-A1 | MATRIPTASE 2 INHIBITORS AND USES THEREOF | MMP7, MATR3, SPINT2 | DRD2 4828/4885DRD3 4796/4885KCNA3 3851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.